Du forlater nå GSKs nettsider

Denne lenken tar deg til en nettside som ikke tilhører GSK. GSK er ikke ansvarlig for, går ikke god for og aksepterer intet ansvar for informasjon eller meninger på nettsteder til tredjeparter

Fortsett

Tilbake

How Nucala works

Nucala is a targeted anti-IL-5 add-on therapy for adults, adolescents and children ≥ 6 years with severe refractory eosinophilic asthma. 1

Nucala is a humanised monoclonal antibody that inhibits the bioactivity of IL-5 12

See how Nucala works. Watch the animation.

Nucala is a humanised monoclonal antibody that inhibits the bioactivity of interleukin (IL)-51Nucala blocks the binding of IL-5 to the alpha chain of the IL-5 receptor complex on the eosinophil cell surface. This inhibits IL-5 signalling and reduces the growth, differentiation, recruitment, activation and survival of eosinophils. 123

What is the pharmacodynamic effect of Nucala?

In clinical studies, Nucala added to high dose ICS and an additional maintenance treatment(s) reduced blood eosinophil levels by 84% compared with placebo added to high dose ICS and an additional maintenance treatment(s). 4

Nucala treatment led to a reduction in geometric mean count from 290 cells/μL (0.29 x 109 cells/L) at baseline to 40 cells/μL (0.04 x 109 cells/L) at Week 32. 1

References:

  1.  Nucala SmPC.
  2. Garcia G, Taillé C, Laveneziana P et al. Anti-interleukin-5 therapy in severe asthma. Eur Respir Rev 2013; 22(129):251–257.
  3. Kouro T and Takatsy K. IL-5- and eosinophil-mediated inflammation: from discovery to therapy. Int Immunol 2009; 21(12):1303–1309.
  4. Ortega H, Liu MC, Pavord ID et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014; 371(13):1198–1207.

Nucala is a trademark of the GSK group of companies